While innovative treatments such as CAR-T cell therapy bring significant potential for curing diseases, payment for such high-cost drugs remains a key hurdle.
Dr. Michael Kolodziej, vice president and chief innovation officer at ADVI Health, tells the American Journal of Managed Care that drug innovation has outpaced modern payment models.
” … Our ability to understand how to pay for those really expensive therapies has not kept up with the science,” he says during the interview. “In fact, the science has outstripped the ability to help patients. And, unfortunately, as a consequence, patients are not getting access to those therapies.”